U.S. markets close in 5 hours 13 minutes
  • S&P 500

    3,452.64
    +25.72 (+0.75%)
     
  • Dow 30

    28,408.23
    +212.81 (+0.75%)
     
  • Nasdaq

    11,529.19
    +50.31 (+0.44%)
     
  • Russell 2000

    1,624.65
    +11.03 (+0.68%)
     
  • Crude Oil

    40.35
    -0.48 (-1.18%)
     
  • Gold

    1,906.90
    -4.80 (-0.25%)
     
  • Silver

    24.78
    +0.09 (+0.35%)
     
  • EUR/USD

    1.1840
    +0.0067 (+0.57%)
     
  • 10-Yr Bond

    0.7870
    +0.0260 (+3.42%)
     
  • GBP/USD

    1.2969
    +0.0028 (+0.22%)
     
  • USD/JPY

    105.5590
    +0.1290 (+0.12%)
     
  • BTC-USD

    11,905.75
    +848.74 (+7.68%)
     
  • CMC Crypto 200

    239.55
    +0.63 (+0.26%)
     
  • FTSE 100

    5,903.63
    +18.98 (+0.32%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

·2 mins read

LOS ANGELES, CA / ACCESSWIRE / September 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Fennec Pharmaceuticals Inc. ("Fennec" or "the Company") (NASDAQ:FENC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 11, 2020 and August 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before November 2, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Fennec's production facilities for its PEDMARK product candidate failed to maintain good manufacturing practices. This failure was likely to delay the regulatory approval of PEDMARK. Based on this news, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fennec, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm



View source version on accesswire.com:
https://www.accesswire.com/607314/SHAREHOLDER-ACTION-NOTICE-The-Schall-Law-Firm-Announces-the-Filing-of-a-Class-Action-Lawsuit-Against-Fennec-Pharmaceuticals-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm